HRP20170051T1 - Dugodjelujući faktori koagulacije i postupci za njihovu proizvodnju - Google Patents
Dugodjelujući faktori koagulacije i postupci za njihovu proizvodnju Download PDFInfo
- Publication number
- HRP20170051T1 HRP20170051T1 HRP20170051TT HRP20170051T HRP20170051T1 HR P20170051 T1 HRP20170051 T1 HR P20170051T1 HR P20170051T T HRP20170051T T HR P20170051TT HR P20170051 T HRP20170051 T HR P20170051T HR P20170051 T1 HRP20170051 T1 HR P20170051T1
- Authority
- HR
- Croatia
- Prior art keywords
- factor
- coagulation factor
- ctps
- carboxy terminal
- seq
- Prior art date
Links
- 108010039209 Blood Coagulation Factors Proteins 0.000 title claims 31
- 102000015081 Blood Coagulation Factors Human genes 0.000 title claims 31
- 239000003114 blood coagulation factor Substances 0.000 title claims 31
- 238000000034 method Methods 0.000 title claims 4
- 101800005309 Carboxy-terminal peptide Proteins 0.000 claims 28
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims 11
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 6
- 102100022641 Coagulation factor IX Human genes 0.000 claims 5
- 102100023804 Coagulation factor VII Human genes 0.000 claims 5
- 108010076282 Factor IX Proteins 0.000 claims 5
- 108010023321 Factor VII Proteins 0.000 claims 5
- 108010054265 Factor VIIa Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 229960004222 factor ix Drugs 0.000 claims 5
- 229940012413 factor vii Drugs 0.000 claims 5
- 229940012414 factor viia Drugs 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 208000031220 Hemophilia Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 229940015047 chorionic gonadotropin Drugs 0.000 claims 2
- 102000006771 Gonadotropins Human genes 0.000 claims 1
- 108010086677 Gonadotropins Proteins 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 239000002622 gonadotropin Substances 0.000 claims 1
- 229940094892 gonadotropins Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Glass Compositions (AREA)
Claims (17)
1. Polipeptid koji sadrži faktor koagulacije i pet ljudskih korionskih gonadotropin karboksi terminalnih peptida (CTP-ova) vezanih na karboksi terminalni kraj navedenog faktora koagulacije, pri čemu navedeni faktor koagulacije je Faktor VII ili Faktor VIIa, ili faktor koagulacije i tri ljudska korionska gonadotropina CTP-a vezana na karboksi terminalni kraj navedenog faktora koagulacije, pri čemu navedeni faktor koagulacije je Faktor IX, pri čemu sekvenca navedenih CTP-ova sadrži prvih 10 amino kiselina iz SEQ ID NO: 4 (tj., sekvencu amino kiseline SSSSKAPPPS).
2. Polipeptid prema zahtjevu 1, naznačen time da sekvenca barem jedne CTP sadrži sekvencu amino kiseline odabranu iz SEQ ID NO: 1 i SEQ ID NO: 2.
3. Polipeptid prema zahtjevu 1 ili 2, naznačen time da barem jedan CTP sadrži barem jedno glikozilacijsko mjesto.
4. Polipeptid prema bilo kojem od zahtjeva 1-3, naznačen time da je barem jedan CTP vezan na navedeni faktor koagulacije preko poveznice.
5. Polipeptid prema zahtjevu 4, naznačen time da navedena poveznica je peptidna veza.
6. Farmaceutski pripravak naznačen time da sadrži polipeptid prema bilo kojem od zahtjeva 1-5.
7. Polinukleotid koji sadrži kodirajući dio koji kodira polipeptid koji se sastoji od faktora koagulacije i pet ljudskih korionskih gonadotropinskih karboksi terminalnih peptida (CTP-ova) vezanih na karboksi terminalni kraj navedenog faktora koagulacije, pri čemu navedeni faktor koagulacije je Faktor VII ili Faktor VIIa, ili kodirajući dio koji kodira polipeptid koji se sastoji od faktora koagulacije i tri ljudska korionska gonadotropinska CTP-a vezana na karboksi terminalni kraj navedenog faktora koagulacije, pri čemu navedeni faktor koagulacije je Faktor IX, pri čemu sekvenca navedenih CTP-ova sadrži prvih 10 amino kiselina iz SEQ ID NO: 4.
8. Polinukleotid prema zahtjevu 7, naznačen time da barem jedan CTP sadrži sekvencu amino kiseline koja je odabrana od SEQ ID NO: 1 i SEQ ID NO: 2.
9. Ekspresijski vektor naznačen time da sadrži polinukleotid prema zahtjevu 7 ili 8.
10. Stanica naznačena time da sadrži ekspresijski vektor prema zahtjevu 9.
11. Pripravak naznačen time da sadrži ekspresijski vektor prema zahtjevu 9.
12. Postupak za produljenje biološkog poluvijeka faktora koagulacije, naznačen time da sadrži korak priključivanje pet ljudskih korionskih gonadotropin karboksi terminalnih peptida (CTP-ova) na karboksi terminalni kraj navedenog faktora koagulacije, pri čemu navedeni faktor koagulacije je Faktor VII ili Faktor VIIa, ili priključivanje tri ljudska korionska gonadotropin CTP-a na karboksi terminalni kraj navedenog faktora koagulacije, pri čemu navedeni faktor koagulacije je Faktor IX, pri čemu sekvenca navedenih CTP-ova sadrži prvih 10 amino kiselina iz SEQ ID NO: 4, čime se poboljšava biološki poluvijek navedenog faktora koagulacije.
13. Postupak za poboljšanje površine pod krivuljom (AUC) faktora koagulacije, naznačen time da sadrži korak priključivanja pet ljudskih korionskih gonadotropina na karboksi terminalne peptide (CTP) na karboksi terminalni kraj navedenog faktora koagulacije, pri čemu navedeni faktor koagulacije je Faktor VII ili Faktor VIIa, ili priključivanja tri ljudska korionska gonadotropin CTP-a na karboksi terminalni kraj navedenog faktora koagulacije, pri čemu navedeni faktor koagulacije je Faktor IX, pri čemu sekvenca navedenih CTP-ova sadrži prvih 10 amino kiselina iz SEQ ID NO: 4, čime se poboljšava AUC navedenog faktora koagulacije.
14. Postupak prema zahtjevu 12 ili 13, naznačen time da je sekvenca amino kiseline od barem jednog korionskog gonadotropina CTP odabrana od SEQ ID NO: 1 i SEQ ID NO: 2.
15. Polipeptid koji se sastoji od faktora koagulacije i pet ljudskih korionskih gonadotropinskih karboksi terminalnih peptida (CTP) vezana na karboksi terminalni kraj navedenog faktora koagulacije, pri čemu sekvence navedenih CTP-ova sadrže prvih 10 amino kiselina iz SEQ ID NO: 4, naznačen time da je za uporabu za liječenje hemofilije, pri čemu navedeni faktor koagulacije je Faktor VII ili Faktor VIIa.
16. Polipeptid koji se sastoji od faktora koagulacije i tri ljudska korionska gonadotropinskih karboksi terminalnih peptida (CTP) vezana na karboksi terminalni kraj navedenog faktora koagulacije, pri čemu sekvence navedenih CTP-ova sadrže prvih 10 amino kiselina iz SEQ ID NO: 4, naznačen time da je za uporabu za liječenje hemofilije, pri čemu navedeni faktor koagulacije je Faktor IX.
17. Polipeptid za uporabu prema zahtjevu 15 ili 16, naznačen time da je sekvenca amino kiseline barem jednog korionskog gonadotropina CTP odabrana od SEQ ID NO: 1 i SEQ ID NO: 2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22436609P | 2009-07-09 | 2009-07-09 | |
| EP10796803.4A EP2451473B1 (en) | 2009-07-09 | 2010-07-01 | Long-acting coagulation factors and methods of producing same |
| PCT/IL2010/000532 WO2011004361A2 (en) | 2009-07-09 | 2010-07-01 | Long-acting coagulation factors and methods of producing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170051T1 true HRP20170051T1 (hr) | 2017-03-24 |
Family
ID=43429620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170051TT HRP20170051T1 (hr) | 2009-07-09 | 2017-01-12 | Dugodjelujući faktori koagulacije i postupci za njihovu proizvodnju |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8476234B2 (hr) |
| EP (2) | EP3130346A1 (hr) |
| JP (3) | JP5823960B2 (hr) |
| KR (3) | KR101802919B1 (hr) |
| CN (2) | CN102639144B (hr) |
| AU (1) | AU2010269884B2 (hr) |
| CA (1) | CA2767503C (hr) |
| CY (1) | CY1118733T1 (hr) |
| DK (1) | DK2451473T3 (hr) |
| ES (1) | ES2618209T3 (hr) |
| HR (1) | HRP20170051T1 (hr) |
| HU (1) | HUE032973T2 (hr) |
| IL (2) | IL235377A (hr) |
| LT (1) | LT2451473T (hr) |
| MX (3) | MX2012000469A (hr) |
| PL (1) | PL2451473T3 (hr) |
| PT (1) | PT2451473T (hr) |
| SI (1) | SI2451473T1 (hr) |
| WO (1) | WO2011004361A2 (hr) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7553940B2 (en) | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting EPO polypeptides and derivatives thereof and methods thereof |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8304386B2 (en) * | 2006-02-03 | 2012-11-06 | Prolor Biotech, Inc. | Long-acting growth hormone and methods of producing same |
| US8476234B2 (en) * | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA3162352A1 (en) | 2010-10-01 | 2012-04-05 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| RU2620072C2 (ru) * | 2011-10-06 | 2017-05-22 | Ханми Сайенс Ко., Лтд. | ПРОИЗВОДНЫЕ ФАКТОРОВ СВЕРТЫВАНИЯ КРОВИ VII И VIIa, КОНЪЮГАТЫ И КОМПЛЕКСЫ, СОДЕРЖАЩИЕ ИХ, И ИХ ПРИМЕНЕНИЕ |
| EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
| KR102310704B1 (ko) * | 2012-02-14 | 2021-10-08 | 옵코 바이오로직스 리미티드 | 장기 작용 응고 인자들 및 이를 생산하는 방법들 |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| AU2013243946A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
| PE20142405A1 (es) * | 2012-04-19 | 2015-01-25 | Opko Biolog Ltd | Variantes de oxintomodulina de accion prolongada y metodos de produccion de las mismas |
| EP2877202A4 (en) * | 2012-07-25 | 2016-06-01 | Biogen Ma Inc | BLOOD FACTOR MONITORING TEST AND USES THEREOF |
| SG10202010383YA (en) * | 2012-11-20 | 2020-11-27 | Opko Biologics Ltd | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides |
| LT2922554T (lt) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminaliai modifikuota rnr |
| US9707276B2 (en) * | 2012-12-03 | 2017-07-18 | Merck Sharp & Dohme Corp. | O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues |
| HRP20231183T1 (hr) | 2013-02-15 | 2024-01-05 | Bioverativ Therapeutics Inc. | Optimizirani gen faktora viii |
| EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| KR20160068969A (ko) * | 2013-10-21 | 2016-06-15 | 옵코 바이오로직스 리미티드 | 장시간-작용하는 폴리펩티드, 그의 생산 방법, 및 그의 투여 방법 |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| RU2021103436A (ru) * | 2014-12-10 | 2021-02-25 | Опко Байолоджикс Лтд. | Способы производства ctp-модифицированных полипептидов гормона роста длительного действия |
| CN108289851B (zh) * | 2015-06-19 | 2021-06-01 | Opko生物科学有限公司 | 长效凝固因子及其产生方法 |
| CN106397571A (zh) * | 2015-07-31 | 2017-02-15 | 李金松 | 一种新型羧基末端肽及长效白介素7 |
| CN106397570B (zh) * | 2015-07-31 | 2019-11-15 | 袁武梅 | 一种羧基末端肽及长效干扰素 |
| US11560418B2 (en) | 2015-10-20 | 2023-01-24 | The University Of North Carolina At Chapel Hill | Methods and compositions for modified factor IX fusion proteins |
| HRP20221089T1 (hr) | 2016-02-01 | 2022-11-25 | Bioverativ Therapeutics Inc. | Optimizirani geni faktora viii |
| KR20240006077A (ko) * | 2016-07-11 | 2024-01-12 | 옵코 바이오로직스 리미티드 | 지속성 응고 인자 vii 및 그 제조 방법 |
| CN107759696A (zh) * | 2016-08-19 | 2018-03-06 | 安源医药科技（上海）有限公司 | 人白介素7融合蛋白及其制备方法 |
| CN106279436B (zh) * | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 活化的人凝血因子vii融合蛋白及其制备方法与用途 |
| CN106279437B (zh) * | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| CN110438022A (zh) * | 2018-10-10 | 2019-11-12 | 福建师范大学 | 一种前体蛋白Kex2过表达毕赤酵母菌株及其构建方法 |
| AU2020242945A1 (en) | 2019-03-19 | 2021-10-14 | CSL Innovation Pty Ltd | Factor IX variants and uses thereof in therapy |
| CN112175088B (zh) * | 2019-07-02 | 2023-03-28 | 江苏晟斯生物制药有限公司 | 改进的fix融合蛋白、缀合物及其应用 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US190611A (en) * | 1877-05-08 | Improvement in protractors | ||
| US130060A (en) * | 1872-07-30 | Improvement in cotton-presses | ||
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| JPS5781447A (en) * | 1980-11-11 | 1982-05-21 | Toyo Jozo Co Ltd | Human chorionic gonadotropic hormone c-terminal fragment |
| US4853332A (en) * | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| DE3421468A1 (de) | 1984-06-08 | 1985-12-19 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| DE122007000007I1 (de) | 1986-04-09 | 2007-05-16 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| ATE110571T1 (de) | 1988-05-06 | 1994-09-15 | Toray Industries | Stabile interferon-beta-zusammensetzung. |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5705478A (en) | 1989-02-21 | 1998-01-06 | Washington University | Covalently linked β subunits of the glycoprotein hormones as antagonists |
| US5338835A (en) * | 1989-02-21 | 1994-08-16 | Washington University | CTP-extended form of FSH |
| US6225449B1 (en) * | 1991-10-04 | 2001-05-01 | Washington University | Hormone analogs with multiple CTP extensions |
| WO1990009800A1 (en) * | 1989-02-21 | 1990-09-07 | Washington University | Modified forms of reproductive hormones |
| US5792460A (en) * | 1989-02-21 | 1998-08-11 | Washington University | Modified glycoprotein hormones having a CTP at the amino terminus |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US7217689B1 (en) * | 1989-10-13 | 2007-05-15 | Amgen Inc. | Glycosylation analogs of erythropoietin |
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| US6028177A (en) | 1991-10-04 | 2000-02-22 | Washington University | Methods of detecting single-chain forms of the glycoprotein hormone quartet |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| JP4156024B2 (ja) | 1993-04-20 | 2008-09-24 | ワシントン ユニバーシティー | 修飾されたタンパク質及びペプチド医薬品 |
| US6737515B2 (en) * | 1993-11-19 | 2004-05-18 | Washington University | Follicle stimulating hormone-glycosylation analogs |
| US6238890B1 (en) | 1994-02-18 | 2001-05-29 | Washington University | Single chain forms of the glycoprotein hormone quartet |
| US5935924A (en) * | 1994-04-15 | 1999-08-10 | Genentech, Inc. | Treatment of congestive heart failure |
| US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
| BR9506313A (pt) | 1994-08-12 | 1997-08-05 | Univ Washington | Formas de cadeia simples do quarteto de hormônio de glicoproteína |
| US6083725A (en) * | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| US20050032211A1 (en) | 1996-09-26 | 2005-02-10 | Metabogal Ltd. | Cell/tissue culturing device, system and method |
| US6310183B1 (en) * | 1997-09-10 | 2001-10-30 | Novo Nordisk A/S | Coagulation factor VIIa composition |
| CN100480266C (zh) | 1998-10-16 | 2009-04-22 | 拜奥根Idec马萨诸塞公司 | 干扰素-β融合蛋白及用途 |
| US6514729B1 (en) * | 1999-05-12 | 2003-02-04 | Xencor, Inc. | Recombinant interferon-beta muteins |
| PE20010288A1 (es) * | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
| US20020127652A1 (en) * | 2000-02-11 | 2002-09-12 | Schambye Hans Thalsgard | Follicle stimulating hormones |
| US7094566B2 (en) * | 2000-03-16 | 2006-08-22 | Amgen Inc., | IL-17 receptor like molecules and uses thereof |
| CA2430934C (en) * | 2000-12-01 | 2011-06-21 | Takeda Chemical Industries, Ltd. | A method of producing sustained-release preparations of a bioactive substance using high-pressure gas |
| JP4409135B2 (ja) | 2000-12-01 | 2010-02-03 | 武田薬品工業株式会社 | 生理活性物質含有製剤の製造法 |
| JP2004528014A (ja) * | 2000-12-07 | 2004-09-16 | イーライ・リリー・アンド・カンパニー | Ｇｌｐ−１融合タンパク質 |
| KR101229995B1 (ko) * | 2000-12-11 | 2013-02-06 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
| DE60117919T2 (de) | 2000-12-11 | 2006-12-14 | Cheil Jedang Corp. | Fusionsprotein mit verbesserter in vivo erythropoietinwirkung |
| US8637077B2 (en) * | 2000-12-28 | 2014-01-28 | Takeda Pharmaceutical Company Limited | Sustained-release preparation |
| JP5160005B2 (ja) | 2000-12-28 | 2013-03-13 | 武田薬品工業株式会社 | 徐放性製剤 |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| CA2471363C (en) * | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7081446B2 (en) * | 2002-01-31 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Long-acting follicle stimulating hormone analogues and uses thereof |
| US7173113B2 (en) * | 2002-01-31 | 2007-02-06 | The Trustees Of Columbia University In The City Of New York | Long-acting hormone and growth factor compositions and uses thereof |
| GB0206048D0 (en) | 2002-03-14 | 2002-04-24 | Croda Int Plc | Use |
| US7459435B2 (en) * | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
| US7459436B2 (en) * | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
| EP1595549A4 (en) * | 2003-02-19 | 2010-09-22 | Takeda Pharmaceutical | DISPERSING AGENT FOR SUSTAINED RELEASE PREPARATIONS |
| JP4683319B2 (ja) | 2003-02-19 | 2011-05-18 | 武田薬品工業株式会社 | 徐放性製剤用の分散剤 |
| WO2005047319A2 (en) * | 2003-11-12 | 2005-05-26 | The University Of Georgia Research Foundation, Inc. | Dna sequence and expressed recombinant glycoproteins related to feline thyrotropin |
| EP1696947B1 (en) * | 2003-12-19 | 2014-02-26 | F.Hoffmann-La Roche Ag | Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases |
| ATE489105T1 (de) * | 2004-03-19 | 2010-12-15 | Baxter Int | Faktor ixa zur behandlung von blutungsstörungen |
| BRPI0514396A2 (pt) * | 2004-08-17 | 2009-05-12 | Csl Behring Gmbh | polipeptìdeos dependentes de vitamina k modificada |
| EP1728798A1 (en) * | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| US8048849B2 (en) * | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US8304386B2 (en) * | 2006-02-03 | 2012-11-06 | Prolor Biotech, Inc. | Long-acting growth hormone and methods of producing same |
| US8048848B2 (en) * | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
| US7553940B2 (en) * | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting EPO polypeptides and derivatives thereof and methods thereof |
| US8476234B2 (en) * | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
-
2010
- 2010-06-30 US US12/826,754 patent/US8476234B2/en active Active
- 2010-07-01 EP EP16187710.5A patent/EP3130346A1/en not_active Ceased
- 2010-07-01 EP EP10796803.4A patent/EP2451473B1/en active Active
- 2010-07-01 MX MX2012000469A patent/MX2012000469A/es active IP Right Grant
- 2010-07-01 HU HUE10796803A patent/HUE032973T2/en unknown
- 2010-07-01 CN CN201080040296.XA patent/CN102639144B/zh active Active
- 2010-07-01 CA CA2767503A patent/CA2767503C/en active Active
- 2010-07-01 SI SI201031374A patent/SI2451473T1/sl unknown
- 2010-07-01 PL PL10796803T patent/PL2451473T3/pl unknown
- 2010-07-01 DK DK10796803.4T patent/DK2451473T3/en active
- 2010-07-01 ES ES10796803.4T patent/ES2618209T3/es active Active
- 2010-07-01 KR KR1020127003469A patent/KR101802919B1/ko active IP Right Grant
- 2010-07-01 KR KR1020177033906A patent/KR101950961B1/ko active Application Filing
- 2010-07-01 MX MX2014010834A patent/MX346920B/es unknown
- 2010-07-01 PT PT107968034T patent/PT2451473T/pt unknown
- 2010-07-01 CN CN201510572447.0A patent/CN105153314A/zh active Pending
- 2010-07-01 AU AU2010269884A patent/AU2010269884B2/en active Active
- 2010-07-01 WO PCT/IL2010/000532 patent/WO2011004361A2/en active Application Filing
- 2010-07-01 LT LTEP10796803.4T patent/LT2451473T/lt unknown
- 2010-07-01 JP JP2012519119A patent/JP5823960B2/ja active Active
- 2010-07-01 KR KR1020197004563A patent/KR102014844B1/ko active IP Right Grant
-
2012
- 2012-01-09 MX MX2021012106A patent/MX2021012106A/es unknown
-
2014
- 2014-10-28 IL IL235377A patent/IL235377A/en active IP Right Grant
-
2015
- 2015-10-08 JP JP2015199912A patent/JP6162769B2/ja active Active
- 2015-10-29 IL IL242368A patent/IL242368B/en active IP Right Grant
-
2017
- 2017-01-12 HR HRP20170051TT patent/HRP20170051T1/hr unknown
- 2017-01-17 CY CY20171100062T patent/CY1118733T1/el unknown
- 2017-06-15 JP JP2017117769A patent/JP6430592B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170051T1 (hr) | Dugodjelujući faktori koagulacije i postupci za njihovu proizvodnju | |
| JP2012532601A5 (hr) | ||
| RU2009106118A (ru) | Способ получения конъюгатов инсулино-подобного фактора роста i и поли(этиленгликоля) | |
| HRP20160798T1 (hr) | Rekombinantni antigeni iz rsv | |
| HRP20200007T1 (hr) | Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba | |
| DE60026300T2 (de) | Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile | |
| HRP20192314T1 (hr) | Pripravci faktora viii i postupci pripreme i njihove uporabe | |
| MX361694B (es) | Fragmentos de peptidos para inducir sintesis de proteinas de matriz extra-celular. | |
| EP3202779A3 (en) | Long-acting hgh polypeptides and uses thereof | |
| NZ621868A (en) | Growth hormone polypeptides and methods of making and using same | |
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| NZ607069A (en) | Modified relaxin polypeptides and their uses | |
| MX2019001925A (es) | Proteina de fusion del factor viii de la coagulacion sanguinea humana altamente glicosilada y metodo de fabricacion y aplicacion del mismo. | |
| RU2011134596A (ru) | Аналоги оксинтомодулина | |
| JP2008534628A (ja) | ペプチド誘導体の製造のための方法 | |
| HRP20130933T1 (hr) | Pripravci sa smanjenom formacijom dimera | |
| WO2017114240A1 (zh) | 一种合成Etelcalcetide的方法 | |
| EA201100038A1 (ru) | Коагонисты глюкагонового рецептора/glp-1-рецептора | |
| EP2573110A3 (en) | Peptide vaccines with Seq Id No: 174, 178, 186 or 194 for cancers expressing tumor-associated antigens | |
| JPH07509228A (ja) | 副甲状腺ホルモンおよび副甲状腺ホルモン関連ペプチドの類似体：それらの合成および骨粗鬆症の処置のための用途 | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| PE20171380A1 (es) | Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada | |
| RU2015103816A (ru) | ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E | |
| NZ599604A (en) | Synthetic myostatin peptide antagonists | |
| HRP20201114T1 (hr) | Dugodjelujući polipeptidi i postupci njihove proizvodnje i primjene |